William Blair Brokers Increase Earnings Estimates for OVID

Ovid Therapeutics Inc. (NASDAQ:OVID) – Analysts at William Blair lifted their Q2 2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will post earnings of $0.23 per share for the quarter, up from their prior forecast of $0.16. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.49) per share.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, August 13th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.34. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.14 million. Ovid Therapeutics had a negative return on equity of 38.24% and a negative net margin of 5,142.56%.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a report on Monday, September 30th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.04.

Ovid Therapeutics Price Performance

OVID opened at $1.15 on Thursday. Ovid Therapeutics has a 1 year low of $0.68 and a 1 year high of $4.10. The stock has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.56. The firm has a market cap of $81.62 million, a PE ratio of -2.60 and a beta of 0.41. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.73 and a quick ratio of 5.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC bought a new stake in Ovid Therapeutics in the 2nd quarter worth approximately $1,077,000. FFT Wealth Management LLC grew its holdings in shares of Ovid Therapeutics by 18.2% in the second quarter. FFT Wealth Management LLC now owns 489,552 shares of the company’s stock worth $377,000 after acquiring an additional 75,530 shares during the period. GSA Capital Partners LLP increased its position in Ovid Therapeutics by 118.0% during the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after acquiring an additional 141,002 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after acquiring an additional 215,189 shares during the period. Finally, Empowered Funds LLC boosted its position in Ovid Therapeutics by 8.1% in the first quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock worth $391,000 after purchasing an additional 9,625 shares during the last quarter. Institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.